Key Points
- COO Melanie Gloria sold 12,626 shares on November 20th at an average price of $23.62 for proceeds of $298,226.12, leaving her with 173,511 shares (a 6.78% reduction, valued at about $4.10M).
- Immunovant shares traded down to $22.59 on heavy volume (1.885M vs. a 1.808M average), with a 12‑month range of $12.72–$29.49, a market cap of $3.96B and a negative PE of -7.95.
- The company missed quarterly EPS expectations (reported -$0.73 vs. -$0.72 expected), analysts expect a -2.69 EPS for the year, and the consensus rating is a Moderate Buy with an average target of $28.78 despite recent price-target cuts and mixed analyst opinions.
Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) COO Melanie Gloria sold 12,626 shares of Immunovant stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $23.62, for a total value of $298,226.12. Following the transaction, the chief operating officer owned 173,511 shares in the company, valued at approximately $4,098,329.82. This represents a 6.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Immunovant Stock Performance
Shares of IMVT stock traded down $0.20 on Friday, hitting $22.59. 1,885,153 shares of the stock traded hands, compared to its average volume of 1,807,647. Immunovant, Inc. has a twelve month low of $12.72 and a twelve month high of $29.49. The firm's 50-day moving average price is $19.36 and its two-hundred day moving average price is $17.05. The stock has a market capitalization of $3.96 billion, a PE ratio of -7.95 and a beta of 0.60.
Immunovant (NASDAQ:IMVT - Get Free Report) last issued its earnings results on Monday, November 10th. The company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.01). During the same period in the prior year, the firm earned ($0.74) EPS. On average, equities research analysts anticipate that Immunovant, Inc. will post -2.69 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research analysts recently commented on the company. JPMorgan Chase & Co. decreased their price objective on Immunovant from $37.00 to $33.00 and set an "overweight" rating on the stock in a report on Tuesday, September 30th. Truist Financial initiated coverage on Immunovant in a research report on Tuesday, October 14th. They issued a "hold" rating and a $16.00 target price on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immunovant in a research note on Tuesday, October 14th. Citigroup reiterated a "buy" rating on shares of Immunovant in a report on Monday, August 11th. Finally, Bank of America reduced their price objective on shares of Immunovant from $33.00 to $30.00 and set a "buy" rating on the stock in a report on Tuesday, August 12th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Immunovant has a consensus rating of "Moderate Buy" and an average target price of $28.78.
Read Our Latest Report on Immunovant
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the company. Arizona State Retirement System boosted its position in shares of Immunovant by 2.2% during the third quarter. Arizona State Retirement System now owns 20,234 shares of the company's stock worth $326,000 after buying an additional 430 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Immunovant by 11.4% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,603 shares of the company's stock worth $106,000 after acquiring an additional 675 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Immunovant by 2.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 36,124 shares of the company's stock valued at $578,000 after acquiring an additional 900 shares during the period. Ameritas Investment Partners Inc. boosted its holdings in Immunovant by 14.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,976 shares of the company's stock valued at $112,000 after acquiring an additional 904 shares during the period. Finally, Strs Ohio acquired a new position in Immunovant in the 1st quarter valued at about $27,000. 47.08% of the stock is currently owned by institutional investors and hedge funds.
Immunovant Company Profile
(
Get Free Report)
Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
